A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 0000-00-00
• Target enrollment: 291
• Participant gender: Both

Summary

To assess the safety, tolerability and efficacy of multiple doses of the drug, CAM-3001 administered in patients with moderately active Rheumatoid Arthritis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MedImmune LLC
• Collaborator: MedImmune Ltd
• Last Updated: 2014-01-13

Criteria

Inclusion Criteria:

Age 18 through 80 years (20 to 75 years in Japan) Diagnosis of adult onset Rheumatoid Arthritis of at least 3 months Functional class I-III defined by the 1992 ACR Classification of Functional Status in RA (Hochberg et al, 1992) Treatment with methotrexate at a stable dose

Exclusion Criteria:

A rheumatic autoimmune disease other than RA. Subjects at a high risk of infection Pregnancy Subjects (male and female) of reproductive potential who are not willing to use contraception from screening through the end date of the trial